Target Information
General Information of This Target
Target ID | PATR0CMGNI |
|||||
---|---|---|---|---|---|---|
Target Name | Protein cereblon (CRBN) |
|||||
Gene Name | CRBN |
|||||
Gene ID | ||||||
Synonym | AD-006 |
|||||
Sequence |
MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYL
GADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTF AVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQA KVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSW PRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLK IGSAIQRLRCELDIMNKCTSLCCKQCQETEITTKNEIFSLSLCGPMAAYVNPHGYVHETL TVYKACNLNLIGRPSTEHSWFPGYAWTVAQCKICASHIGWKFTATKKDMSPQKFWGLTRS ALLPTIPDTEDEISPDKVILCL Click to Show/Hide
|
|||||
Family | the CRBN family |
|||||
Function |
Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteinssuch as MEIS2 or ILF2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. Maintains presynaptic glutamate release and consequently cognitive functionssuch as memory and learningby negatively regulating large-conductance calcium-activated potassium (BK) channels in excitatory neurons. Likely to function by regulating the assembly and neuronal surface expression of BK channels via its interaction with KCNT1. May also be involved in regulating anxiety-like behaviors via a BK channel-independent mechanism. Plays a negative role in TLR4 signaling by interacting with TRAF6 and ECSITleading to inhibition of ECSIT ubiquitinationan important step of the signaling.
Click to Show/Hide
|
|||||
Uniprot Entry | ||||||
HGNC ID | ||||||
KEGG ID |
Full List of The ADC Related to This Target
Investigative
ADC Info | ADC Name | Antibody | Antigen | Payload | Linker | Ref |
---|---|---|---|---|---|---|
Rituximab-Compound (la) DAR 8 |
Rituximab |
MS4A1 |
NeoDegrader P1 |
Rituximab-Compound (la) linker |
[1] | |
Pertuzumab-Compound(la) |
Pertuzumab |
ERBB2 |
NeoDegrader P1 |
Pertuzumab-Compound(la) linker |
[1] | |
Trastuzumab-Compound (la) DAR 1.6 |
Trastuzumab |
ERBB2 |
NeoDegrader P1 |
Trastuzumab-Compound (la) DAR 1.6 linker |
[1] | |
Trastuzumab-Compound (la) DAR 8 |
Trastuzumab |
ERBB2 |
NeoDegrader P1 |
Trastuzumab-Compound (la) DAR 8 linker |
[1] | |
Pertuzumab-Compound (la) DAR 8 |
Pertuzumab |
ERBB2 |
NeoDegrader P1 |
Pertuzumab-Compound (la) DAR 8 linker |
[1] | |
OR000213-Compound (Ia) |
OR000213 |
CD33 |
NeoDegrader P1 |
OR000213-Compound (Ia) linker |
[1] | |
huMy9-6IgG1-Compound (la) DAR 8 |
huMy9-6 IgG1 |
CD33 |
NeoDegrader P1 |
huMy9-6IgG1-Compound (la) DAR 8 linker |
[1] | |
Lintuzumab IgG1-Compound (la) DAR 8 |
Lintuzumab |
CD33 |
NeoDegrader P1 |
Lintuzumab IgG1-Compound (la) DAR 8 linker |
[1] | |
OR000213-Compound(la) DAR 8 |
OR000213 |
CD33 |
NeoDegrader P1 |
OR000213-Compound(la) DAR 8 linker |
[1] | |
huMy9-6 IgG1-Compound (la) DAR 1.9 |
huMy9-6 IgG1 |
CD33 |
NeoDegrader P1 |
huMy9-6 IgG1-Compound (la) DAR 1.9 linker |
[1] | |
huMy9-6IgG1-Compound (la) DAR3.9 |
huMy9-6 IgG1 |
CD33 |
NeoDegrader P1 |
huMy9-6IgG1-Compound (la) DAR3.9 linker |
[1] | |
huMy9-6IgG1-Compound(la) DAR 5.5 |
huMy9-6 IgG1 |
CD33 |
NeoDegrader P1 |
huMy9-6IgG1-Compound(la) DAR 5.5 linker |
[1] | |
OR000213-Compound (la) DAR 1.2 |
OR000213 |
CD33 |
NeoDegrader P1 |
OR000213-Compound (la) DAR 1.2 linker |
[1] | |
OR000213-Compound(la) DAR 1.8 |
OR000213 |
CD33 |
NeoDegrader P1 |
OR000213-Compound(la) DAR 1.8 linker |
[1] | |
OR000213-Compound(la) DAR 2.3 |
OR000213 |
CD33 |
NeoDegrader P1 |
OR000213-Compound(la) DAR 2.3 linker |
[1] | |
Trastuzumab-Compound (Ib) DAR1.5 |
Trastuzumab |
ERBB2 |
NeoDegrader P3 |
Trastuzumab-Compound (Ib) DAR1.5 linker |
[1] | |
Trastuzumab-Compound (lc) |
Trastuzumab |
ERBB2 |
NeoDegrader P4 |
Trastuzumab-Compound (lc) linker |
[1] | |
Rituximab-Compound (lc) |
Rituximab |
MS4A1 |
NeoDegrader P4 |
Rituximab-Compound (lc) linker |
[1] | |
Pertuzumab-Compound(lc) |
Pertuzumab |
ERBB2 |
NeoDegrader P4 |
Pertuzumab-Compound(lc) linker |
[1] | |
Trastuzumab-Compound (lc) DAR 8 |
Trastuzumab |
ERBB2 |
NeoDegrader P4 |
Trastuzumab-Compound (lc) DAR 8 linker |
[1] | |
Pertuzumab-Compound (lc) DAR 8 |
Pertuzumab |
ERBB2 |
NeoDegrader P4 |
Pertuzumab-Compound (lc) DAR 8 linker |
[1] | |
Trastuzumab-Compound (ld) DAR 1.6 |
Trastuzumab |
ERBB2 |
NeoDegrader P1 |
Trastuzumab-Compound (ld) DAR 1.6 linker |
[1] | |
huMy9-6IgG1-Compound (ld) DAR 8 |
huMy9-6 IgG1 |
CD33 |
NeoDegrader P1 |
huMy9-6IgG1-Compound (ld) DAR 8 linker |
[1] | |
Lintuzumab IgG1-Compound (ld) DAR 8 |
Lintuzumab |
CD33 |
NeoDegrader P1 |
Lintuzumab IgG1-Compound (ld) DAR 8 linker |
[1] | |
Trastuzumab-Compound (le) |
Trastuzumab |
ERBB2 |
NeoDegrader P1 |
Trastuzumab-Compound (le) linker |
[1] | |
Rituximab-Compound (le) |
Rituximab |
MS4A1 |
NeoDegrader P1 |
Rituximab-Compound (le) linker |
[1] | |
Pertuzumab-Compound (le) |
Pertuzumab |
ERBB2 |
NeoDegrader P1 |
Pertuzumab-Compound (le) linker |
[1] | |
Trastuzumab-Compound (lf) |
Trastuzumab |
ERBB2 |
NeoDegrader P6 |
Trastuzumab-Compound (lf) linker |
[1] | |
Rituximab-Compound (lf) |
Rituximab |
MS4A1 |
NeoDegrader P6 |
Rituximab-Compound (lf) linker |
[1] | |
Pertuzumab-Compound (lf) |
Pertuzumab |
ERBB2 |
NeoDegrader P6 |
Pertuzumab-Compound (lf) linker |
[1] | |
Trastuzumab-Compound (lg) |
Trastuzumab |
ERBB2 |
NeoDegrader P2 |
Trastuzumab-Compound (lg) linker |
[1] | |
Rituximab-Compound (lg) |
Rituximab |
MS4A1 |
NeoDegrader P2 |
Rituximab-Compound (lg) linker |
[1] | |
Pertuzumab-Compound (lg) |
Pertuzumab |
ERBB2 |
NeoDegrader P2 |
Pertuzumab-Compound (lg) linker |
[1] | |
Trastuzumab-Compound (lh) |
Trastuzumab |
ERBB2 |
NeoDegrader P13 |
Trastuzumab-Compound (lh) linker |
[1] | |
Rituximab-Compound (lh) |
Rituximab |
MS4A1 |
NeoDegrader P13 |
Rituximab-Compound (lh) linker |
[1] | |
Pertuzumab-Compound (lh) |
Pertuzumab |
ERBB2 |
NeoDegrader P13 |
Pertuzumab-Compound (lh) linker |
[1] | |
Trastuzumab-Compound (li) |
Trastuzumab |
ERBB2 |
NeoDegrader P1 |
Trastuzumab-Compound (li) linker |
[1] | |
Rituximab-Compound (li) |
Rituximab |
MS4A1 |
NeoDegrader P1 |
Rituximab-Compound (li) linker |
[1] | |
Pertuzumab-Compound (li) |
Pertuzumab |
ERBB2 |
NeoDegrader P1 |
Pertuzumab-Compound (li) linker |
[1] | |
Trastuzumab-Compound (lk) |
Trastuzumab |
ERBB2 |
NeoDegrader P14 |
Trastuzumab-Compound (lk) linker |
[1] | |
Rituximab-Compound (lk) |
Rituximab |
MS4A1 |
NeoDegrader P14 |
Rituximab-Compound (lk) linker |
[1] | |
Pertuzumab-Compound (lk) |
Pertuzumab |
ERBB2 |
NeoDegrader P14 |
Pertuzumab-Compound (lk) linker |
[1] | |
Trastuzumab-Compound (ll) |
Trastuzumab |
ERBB2 |
NeoDegrader P14 |
Trastuzumab-Compound (ll) linker |
[1] | |
Rituximab-Compound (ll) |
Rituximab |
MS4A1 |
NeoDegrader P14 |
Rituximab-Compound (ll) linker |
[1] | |
Pertuzumab-Compound (ll) |
Pertuzumab |
ERBB2 |
NeoDegrader P14 |
Pertuzumab-Compound (ll) linker |
[1] | |
Trastuzumab-Compound (lm) |
Trastuzumab |
ERBB2 |
NeoDegrader P14 |
Trastuzumab-Compound (lm) linker |
[1] | |
Rituximab-Compound (lm) |
Rituximab |
MS4A1 |
NeoDegrader P14 |
Rituximab-Compound (lm) linker |
[1] | |
Pertuzumab-Compound (lm) |
Pertuzumab |
ERBB2 |
NeoDegrader P14 |
Pertuzumab-Compound (lm) linker |
[1] | |
Rituximab-Compound (la) DAR 4 |
Rituximab |
MS4A1 |
NeoDegrader P1 |
Rituximab-Compound (la) linker |
[1] | |
HuAT12/5-Compound (Ia) |
HuAT12/5 |
CD38 |
NeoDegrader P1 |
HuAT12/5-Compound (Ia) linker |
[1] | |
Isatuximab-Compound (Ia) |
Isatuximab |
CD38 |
NeoDegrader P1 |
Isatuximab-Compound (Ia) linker |
[1] | |
Daratumumab-Compound (Ia) |
Daratumumab |
CD38 |
NeoDegrader P1 |
Daratumumab-Compound (Ia) linker |
[1] | |
Indatuximab-Compound (Ia) |
Indatuximab |
CD38 |
NeoDegrader P1 |
Indatuximab-Compound (Ia) linker |
[1] | |
Belantamab-Compound (Ia) |
Belantamab |
TNFRSF17 |
NeoDegrader P1 |
Belantamab-Compound (Ia) linker |
[1] | |
Sacituzumab-Compound (Ia) |
Sacituzumab |
TACSTD2 |
NeoDegrader P1 |
Sacituzumab-Compound (Ia) linker |
[1] | |
U3-1784-Compound (Ia) |
U3-1784 |
FGFR4 |
NeoDegrader P1 |
U3-1784-Compound (Ia) linker |
[1] | |
Cetuximab-Comound (Ia) |
Cetuximab |
EGFR |
NeoDegrader P1 |
Cetuximab-Comound (Ia) linker |
[1] | |
Olaratumab-Compound (Ia) |
Olaratumab |
PDGFRA |
NeoDegrader P1 |
Olaratumab-Compound (Ia) linker |
[1] | |
Ontuxizumab-Compound (Ia) |
Ontuxizumab |
CD248 |
NeoDegrader P1 |
Ontuxizumab-Compound (Ia) linker |
[1] | |
Anti-CD33AB-Compound (Ia) |
Anti-CD33AB |
CD33 |
NeoDegrader P1 |
Anti-CD33AB-Compound (Ia) linker |
[2] | |
Anti-CD33AB-Compound (Ib) |
Anti-CD33AB |
CD33 |
NeoDegrader P1 |
Anti-CD33AB-Compound (Ib) linker |
[2] | |
Anti-CD33AB-Compound (Ic) |
Anti-CD33AB |
CD33 |
NeoDegrader P1 |
Anti-CD33AB-Compound (Ic) linker |
[2] | |
Anti-CD33AB-Compound (Ie) |
Anti-CD33AB |
CD33 |
NeoDegrader P1 |
Anti-CD33AB-Compound (Ie) linker |
[2] | |
Anti-CD33AB-Compound (Ih) |
Anti-CD33AB |
CD33 |
NeoDegrader P1 |
Anti-CD33AB-Compound (Ih) linker |
[2] | |
Gemtuzumab-Compound (Ia) |
Gemtuzumab |
CD33 |
NeoDegrader P1 |
Gemtuzumab-Compound (Ia) linker |
[2] | |
Gemtuzumab-Compound (Ib) |
Gemtuzumab |
CD33 |
NeoDegrader P1 |
Gemtuzumab-Compound (Ib) linker |
[2] | |
Gemtuzumab-Compound (Ic) |
Gemtuzumab |
CD33 |
NeoDegrader P1 |
Gemtuzumab-Compound (Ic) linker |
[2] | |
Gemtuzumab-Compound (Ie) |
Gemtuzumab |
CD33 |
NeoDegrader P1 |
Gemtuzumab-Compound (Ie) linker |
[2] | |
Gemtuzumab-Compound (Ih) |
Gemtuzumab |
CD33 |
NeoDegrader P1 |
Gemtuzumab-Compound (Ih) linker |
[2] | |
huMy9-6-IgG4-S228P-Compound (Ia) |
huMy9-6-IgG4-S228P |
CD33 |
NeoDegrader P1 |
huMy9-6-IgG4-S228P-Compound (Ia) linker |
[2] | |
huMy9-6-IgG4-S228P-Compound (Ib) |
huMy9-6-IgG4-S228P |
CD33 |
NeoDegrader P1 |
huMy9-6-IgG4-S228P-Compound (Ib) linker |
[2] | |
huMy9-6-IgG4-S228P-Compound (Ic) |
huMy9-6-IgG4-S228P |
CD33 |
NeoDegrader P1 |
huMy9-6-IgG4-S228P-Compound (Ic) linker |
[2] | |
huMy9-6-IgG4-S228P-Compound (Ie) |
huMy9-6-IgG4-S228P |
CD33 |
NeoDegrader P1 |
huMy9-6-IgG4-S228P-Compound (Ie) linker |
[2] | |
huMy9-6-IgG4-S228P-Compound (Ih) |
huMy9-6-IgG4-S228P |
CD33 |
NeoDegrader P1 |
huMy9-6-IgG4-S228P-Compound (Ih) linker |
[2] | |
Anti-CD33 AB1 Compound (Ia) |
Anti-CD33 AB1 |
CD33 |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Ia) linker |
[3] | |
Anti-CD33 AB1 Compound (Ib) |
Anti-CD33 AB1 |
CD33 |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Ib) linker |
[3] | |
Anti-CD33 AB1 Compound (Ic) |
Anti-CD33 AB1 |
CD33 |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Ic) linker |
[3] | |
Anti-CD33 AB1 Compound (Id) |
Anti-CD33 AB1 |
CD33 |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Id) linker |
[3] | |
Anti-CD33 AB1 Compound (Ie) |
Anti-CD33 AB1 |
CD33 |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Ie) linker |
[3] | |
Anti-CD33 AB1 Compound (If) |
Anti-CD33 AB1 |
CD33 |
NeoDegrader P6 |
Anti-CD33 AB1 Compound (If) linker |
[3] | |
Anti-CD33 AB1 Compound (Ig) |
Anti-CD33 AB1 |
CD33 |
NeoDegrader P2 |
Anti-CD33 AB1 Compound (Ig) linker |
[3] | |
Anti-CD33 AB1 Compound (Ih) |
Anti-CD33 AB1 |
CD33 |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Ih) linker |
[3] | |
Anti-CD33 AB1 Compound (Ii) |
Anti-CD33 AB1 |
CD33 |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Ii) linker |
[3] | |
Anti-CD33 AB1 Compound (Ik) |
Anti-CD33 AB1 |
CD33 |
NeoDegrader P14 |
Anti-CD33 AB1 Compound (Ik) linker |
[3] | |
Anti-CD33 AB1 Compound (Il) |
Anti-CD33 AB1 |
CD33 |
NeoDegrader P14 |
Anti-CD33 AB1 Compound (Il) linker |
[3] | |
Anti-CD33 AB1 Compound (Im) |
Anti-CD33 AB1 |
CD33 |
NeoDegrader P14 |
Anti-CD33 AB1 Compound (Im) linker |
[3] | |
Trastuzumab-Compound (lj) |
Trastuzumab |
ERBB2 |
NeoDegrader P1 |
Trastuzumab-Compound (lj) linker |
[1] | |
Rituximab-Compound (lj) |
Rituximab |
MS4A1 |
NeoDegrader P1 |
Rituximab-Compound (lj) linker |
[1] | |
Pertuzumab-Compound (lj) |
Pertuzumab |
ERBB2 |
NeoDegrader P1 |
Pertuzumab-Compound (lj) linker |
[1] | |
Anti-CD33 AB1 Compound (Ij) |
Anti-CD33 AB1 |
CD33 |
NeoDegrader P1 |
Anti-CD33 AB1 Compound (Ij) linker |
[3] |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.